Hepatocellular Carcinoma: Screening and Staging

Clinics in Liver Disease

Volumn 15, Issue 2, 2011, Pages 323-334

  Sherman, Morris ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

BCLC staging system; Hepatocellular carcinoma; Screening for hcc; Staging of hcc

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; SORAFENIB;

ALCOHOL CONSUMPTION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CHRONIC LIVER DISEASE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENDOSCOPIC ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FOLLOW UP; HEALTH CARE COST; HEPATITIS B; HEPATITIS C; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR GROWTH;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MASS SCREENING; NEOPLASM STAGING; PROGNOSIS;

EID: 79959323446     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.03.003     Document Type: Review

References (47)

1. Zhang B.H., Yang B.H., Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004, 130:417-422.
2. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Available at: Accessed February 7, 2010. http://www.aasld.org/practiceguidelines/documents/bookmarked%20practice%20guidelines/hccupdate2010.pdf.
3. Arguedas M.R., Chen V.K., Eloubeidi M.A., et al. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003, 98:679-690.
4. Nouso K., Tanaka H., Uematsu S., et al. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol 2008, 23:437-444.
5. Lin O.S., Keeffe E.B., Sanders G.D., et al. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004, 19:1159-1172.
6. Thompson Coon J., Rogers G., Hewson P., et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess 2007, 11:1-206.
7. Andersson K.L., Salomon J.A., Goldie S.J., et al. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008, 6:1418-1424.
8. Patel D., Terrault N.A., Yao F.Y., et al. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005, 3:75-84.
9. Sarasin F.P., Giostra E., Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996, 101:422-434. Kang et al. J Gastro Hepatol 1992.
10. Saab S., Ly D., Nieto J., et al. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl 2003, 9:672-681.
11. Shih S.T., Crowley S., Sheu J.C. Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan. J Formos Med Assoc 2010, 109(1):39-55.
12. Collier J., Krahn M., Sherman M. A cost-benefit analysis of the benefit of screening for hepatocellular carcinoma. Hepatology 1999, 30:481A.
13. Yuen M.F., Tanaka Y., Fong D.Y., et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009, 50(1):80-88.
14. Yang H.I., Sherman M., Su J., et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010, 28(14):2437-2444.
15. Lok A.S., Seeff L.B., Morgan T.R., et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009, 136(1):138-148.
16. Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295(1):65-73.
17. Sala M., Llovet J.M., Vilana R., et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004, 40:1352-1360.
18. Trevisani F., D'Intino P.E., Morselli-Labate A.M., et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001, 34(4):570-575.
19. Pateron D., Ganne N., Trinchet J.C., et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994, 20:65-71. [see comments].
20. Zoli M., Magalotti D., Bianchi G., et al. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996, 78:977-985.
21. Izuno K., Fujiyama S., Yamasaki K., et al. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study. Hepatogastroenterology 1995, 42:387-393.
22. Lok A.S., Sterling R.K., Everhart J.E., et al. Des-gamma-carboxy prothrombin and alpha fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010, 138(2):493-502.
23. Marrero J.A., Feng Z., Wang Y., et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009, 137(1):110-118.
24. Grazi G.L., Mazziotti A., Legnani C., et al. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg 1995, 1:249-255.
25. Tsai S.L., Huang G.T., Yang P.M., et al. Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma. Hepatology 1990, 11:481-488.
26. Suehiro T., Sugimachi K., Matsumata T., et al. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha-fetoprotein. Cancer 1994, 73:2464-2471.
27. Marrero J.A., Su G.L., Wei W., et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003, 37:1114-1121.
28. Singal A., Volk M.L., Waljee A., et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009, 30(1):37-47.
29. Bolondi L., Sofia S., Siringo S., et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effectiveness analysis. Gut 2001, 48:251-259.
30. Chen T.H., Chen C.J., Yen M.F., et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 2002, 98:257-261.
31. Larcos G., Sorokopud H., Berry G., et al. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. AJR Am J Roentgenol 1998, 171:433-435.
32. Snowberger N., Chinnakotla S., Lepe R.M., et al. Alpha fetoprotein, ultrasound, computerized tomography and magnetic resonance imaging for detection of hepatocellular carcinoma in patients with advanced cirrhosis. Aliment Pharmacol Ther 2007, 26:1187-1194.
33. Zhang B., Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 1999, 6:108-110.
34. Kim D.Y., Han K.H., Ahn S.H., et al. Semiannual surveillance for hepatocellular carcinoma improved patient survival compared to annual surveillance (Korean experience). Hepatology 2007, 46(Suppl 1):403A.
35. Stravitz R.T., Heuman D.M., Chand N., et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008, 121(2):119-126.
36. Welch H.G., Black W.C. Overdiagnosis in cancer. J Natl Cancer Inst 2010, 102(9):605-613.
37. Okuda K., Kubo Y. Clinical types of hepatocellular carcinoma and correlation between liver pathology and clinical manifestations. Kurume Med J 1979, 26(3):247-260.
38. Leung T.W., Tang A.M., Zee B., et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002, 94(6):1760-1769.
39. Minagawa M., Ikai I., Matsuyama Y., et al. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 2007, 245(6):909-922.
40. The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000, 31(4):840-845.
41. Chevret S., Trinchet J.C., Mathieu D., et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999, 31(1):133-141.
42. Sala M., Forner A., Varela M., et al. Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis 2005, 25(2):171-180.
43. Vauthey J.N., Lauwers G.Y., Esnaola N.F., et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 2002, 20(6):1527-1536.
44. Kudo M., Chung H., Haji S., et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004, 40(6):1396-1405.
45. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4):378-390.
46. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10(1):25-34.
47. Llovet J.M., Bustamante J., Castells A., et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999, 29(1):62-67.